Renal Business Today

Survey: Anemia Managers Targeting Lower Hemoglobin

EXTON, Pa.— In the dialysis and chronic kidney disease non-dialysis (CKD-ND) settings, holding erythropoiesis-stimulating agents (ESAs) at lower hemoglobin levels and lower hemoglobin targets are the most common recent changes reported by anemia managers, according to a new ...More

September 28, 2010

Posted in News, Practice Management

Amgen Recalls Epogen, Procrit Due to Glass Flakes

THOUSAND OAKS, Calif.—Amgen has issued a voluntary recall of certain lots of the anemia drugs Epogen and Procrit because they could contain thin glass flakes, according to a Sept. 24 news release. ...More

September 24, 2010

Posted in News, Clinical & Pharma, Government & Regulation

Anemia Study Changed Way Docs Prescribe ESAs

EXTON, Pa.—Recent clinical reports on erythropoietin-stimulating agents have changed the way nephrologists are prescribing anemia drugs, according to recent survey results from BioTrends Research ...More

April 27, 2010

Posted in News, Business, Clinical & Pharma, Practice Management

FDA to Review 3 Anemia Drugs for Safety

The U.S. Food and Drug Administration (FDA) said yesterday it would review the safety of Amgen’s Aranesp and Epogen and Johnson & Johnson’s Procrit anemia drugs after clinical trials raised "major concerns regarding the use of ESAs to increase hemoglobin concentrations" ...More

January 7, 2010

Posted in News, Business, Clinical & Pharma, Government & Regulation

Nearly Half of Dialysis Clinics Do Not Specify Hemoglobin Range

WASHINGTON—Only 56 percent of Medicare-certified dialysis clinics have anemia drug administration protocols in place that explicitly state a target hemoglobin range for patients, according to a recent government review of dialysis facilities. ...More

November 10, 2009

Posted in News, Business, Clinical & Pharma, Government & Regulation, Practice Management

Report: Product Shifts in Renal Anemia, Bone, Mineral Metabolism Markets

EXTON, Pa.—Product shifts are occurring in the renal anemia and bone and mineral metabolism markets, according to BioTrends Research Group’s most recent TreatmentTrends®: US Nephrology Report syndicated report based on online survey results of more than 200 ...More

April 28, 2009

Posted in News, Business, Clinical & Pharma, Practice Management

Va. Doctor Indicted on 45 Counts of Healthcare Fraud

VIRGINIA BEACH, Va.—Ronald Poulin, MD, a hematologist and oncologist, was indicted in federal court April 3 on charges of defrauding Medicare and Tricare, the health insurance program for military families, by more than $850,000 over the past three years, reported the ...More

April 6, 2009

Posted in News, Clinical & Pharma, Government & Regulation

FDA Releases Q&A about ESA Medication Guides

BETHESDA, Md.—FDA released answers to questions regarding the use of erythropoiesis-stimulating agents (ESAs) and their FDA-approved Medication Guides, which are now part of labeling for ESAs Aranesp®, Epogen® and Procrit®. ...More

December 9, 2008

Posted in News, Clinical & Pharma, Government & Regulation

Anemia managers placing more emphasis on IV iron

EXTON, Pa.— Anemia managers for dialysis patients are more likely to report that they are using lower average doses of erythropoiesis-stimulating agents, monitoring hemoglobins more frequently and placing more emphasis on a patient's IV iron status, according to a report ...More

September 12, 2008

Posted in News, Business, Clinical & Pharma

ESA use decreases in pre-dialysis patients, study says

EXTON, Pa.—Safety concerns regarding anemia drugs have led to a decrease in the use of erythropoiesis-stimulating agents in predialysis patients, according to a recent report. ...More

May 7, 2008

Posted in News, Business, Clinical & Pharma, Government & Regulation

Computers & Software	Consulting, Management...
Equipment & Services	Hemodialysis Supplies
Patient Services	More Options...

Procrit

Video Snapshot

Galleries

RBT Poll

Most Popular Articles

Buyer's Guide

Resources

Free Email Updates

featured links

First Name	Last Name
E-Mail